Bachelors educated Registered Nurse with seven years of experience two of which were cardiology research, clinical knowledge, EMR/EHR charting, medication administration, interdisciplinary collaboration, natural interpersonal strengths and technical abilities dedicated to providing compassionate, appropriate and efficient patient care.
I am organized and efficient. I have implemented new paperwork or computer systems in every position I have held to streamline work processes. I bring my critical thinking skills to the table when working alone or with a team. I am detail oriented. I have used EPIC EMR/EHR in many different settings, as a pharmacy technician, nursing student, clinical nurse research coordinator and perioperative nurse. I am a well liked and dependable team member. I learn quickly and am not afraid to take on new tasks, responsibilities or challenges. I currently have my ACLS, BLS and PALS certifications from AHA and hold a multi-state nursing license with the Nurse Licensure Compact.
Graduated with Honors
Sigma Theta Tau International Honors Society of Nurses
Graduated with Honors
ABSORB IV: 10-392. A Prospective, Randomized, Single-blind, Multi-center Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions.
COBRA-REDUCE: COBRA 2015-01. Randomized trial of Cobra PzF Stenting to Reduce Duration of Triple Therapy (COBRA-REDUCE)
CSL: CSL112_2001. A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Moderate Renal Impairment and Acute Myocardial Infarction.
DREAM HF-1: MSB-MPC-CHF001. A Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology
GALACTIC HF: 20110203. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction
HEART-FID: 1VIT115043. A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency.
LEADERS: 16US01. A Prospective Study of the BIOFREEDOM TM BIOLIMUS A9 TM Drug Coated Stent in patients at high risk for bleeding.
PANACHE: BAY 1067197/17582. A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetics and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure and preserved ejection fraction.
PIONEER: CLCZ696BUS01. A multicenter, randomized, double-blind, double dummy, parallel group, active-controlled 8-week study to evaluate the effect of sacubitril and valsartan (LCZ696) versus enalapril on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696 compared to enalapril in HFrEF patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF).
REDUAL PCI: 1160.186. A prospective Randomized, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0-3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting.
RENAL GUARD: RGS001D. A Study to Evaluate Renal Guard™ System Safety & Efficacy when compared with standard care in the prevention of Contrast Induced Nephropathy in the Setting of a Catheterization Laboratory
SPARTAN: 201702750. A Pharmacodynamic study comparing prasugrel versus ticagrelor in patients with coronary artery disease undergoing PCI with CYP2C19 loss-of-function genotypes:
A feasibility study with point-of-care pharmacodynamic and genetic testing
TWILIGHT: 2015-172. Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
VICTORIA: MK-1242-001-00. A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral Sgc Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction
Resumes, and other information uploaded or provided by the user, are considered User Content governed by our Terms & Conditions. As such, it is not owned by us, and it is the user who retains ownership over such content.
Job Titles Held: